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Introduction: Diffuse systemic sclerosis is associated with high mortality; however, the pathogenesis of cardiac
death in these patients is not clear.
Case presentation: A 56-year-old Caucasian female patient presented with dyspnea and requested to donate her
body to science in order to improve understanding of diffuse systemic sclerosis pathogenesis. She had extensive
testing for dyspnea including pulmonary function tests, an echocardiogram, cardiac magnetic resonance imaging,
and right heart catheterization to characterize her condition. Her case highlights the morbidity seen in this disease,
including the presence of extensive skin thickening, digital ulcerations, and scleroderma renal crisis.
Conclusion: In this case report, we present the finding of cardiac tissue metabolomics, which may indicate a
problem with vasodilation as a contributor to cardiac death in diffuse systemic sclerosis. The use of autopsy and
tissue metabolomics in rare disease may help clarify disease pathogenesis.
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Diffuse systemic sclerosis (SSc) is associated with a high
morbidity and mortality, and collaborative efforts are
needed to understand its pathogenesis [1]. The Prospect-
ive Registry of Early Systemic Sclerosis (PRESS), a multi-
center incident cohort study of patients with early
diffuse cutaneous SSc, has the goal of advancing the un-
derstanding of disease pathogenesis and identifying
novel biomarkers [2]. The PRESS investigators elected to
study patients with recently diagnosed diffuse SSc initi-
ated on appropriate treatment to examine predictors of
these patients’ morbidity and mortality. We present a
case report of a PRESS patient who requested to donate
her body to science to highlight the importance of using
autopsy to better understand mortality in this rare dis-
ease. This is the first case report of using cardiac tissue* Correspondence: Tracy.Frech@hsc.utah.edu
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pathogenesis.Case presentation
A 56-year-old Caucasian woman with a 20-year history
of type II diabetes mellitus presented with increased fa-
tigue, bilateral lower extremity edema, and tightness of
her skin in her lower extremities in 2012. Her primary
care physician evaluated her cellular blood counts, chem-
istries, and thyroid-stimulating hormone, and obtained an
echocardiogram. All of these studies were normal. A sleep
study revealed mild obstructive sleep apnea, which was
treated.
Within six months, in addition to lower extremity
skin thickening, she developed dyspnea, Raynaud’s
phenomenon, and digital ulcerations. She was re-
ferred to a rheumatologist at that time and found to be
positive for anti-nuclear antibodies, at 1:640 in a nucleolar
pattern, and RNA polymerase III antibody. Tests for
other SSc antibodies, including anti-centromere, anti-icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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tive. Her blood pressure and creatinine were noted to be
normal. Her hemoglobin A1c was 7.6%. She was not on
an angiotensin-converting enzyme inhibitor (ACE-I).
At a rheumatology appointment six months after her
initial symptoms started, pulmonary function tests dem-
onstrated an isolated decrease in diffusing capacity (38%
predicted). A repeat echocardiogram suggested the in-
terim development of moderate pulmonary hypertension
with an estimated right ventricular systolic pressure of
45mmHg and an impaired relaxation pattern of left ven-
tricular filling. A computed tomography scan of her
chest did not reveal the presence of a pulmonary embol-
ism, and there was no evidence of interstitial lung dis-
ease. Cardiac magnetic resonance imaging (MRI) did not
show any delayed enhancement that would suggest prior
myocardial injury or infarction. The images revealed that
she had normal stress and resting perfusion, as well as
hyperdynamic left ventricular function with an ejection
fraction of 77% and no wall motion abnormalities. How-
ever, there was mild bi-atrial enlargement and her right
ventricle was dilated with normal right ventricular systolic
function. A right heart catheterization established the diag-
nosis of pulmonary hypertension, with right atrial pressure
of 12mmHg, right ventricular pressure of 53/17mmHg,
pulmonary arterial (PA) pressure of 45/16mmHg (mean,
33mmHg), wedge pressure of 20mmHg, cardiac output
of 7L/min, cardiac index of 3.5L/min, and peripheral
vascular resistance of 2 Wood units. She was noted to
be anemic with a hemoglobin level of 7.4g/dL.
Based on her cardiac catheterization results, she was
treated with diuresis and a phosphodiesterase 5 inhibi-
tor. At her one-month follow-up visit after the cardiac
catheterization, her digital ulcerations were healing and
lower extremity edema was improved, but her modified
Rodnan skin score had worsened by six points (27 to
33). Methotrexate was prescribed, but our patient re-
ported intolerable nausea after two doses. Owing to the
anemia, she had an upper endoscopy. This led to a diag-
nosis of gastric antral vascular ectasia that was treated
with argon plasma coagulation. Our patient was hesitant
to continue methotrexate, thus mycophenolate mofetil
was prescribed. Our patient did not receive any steroid
therapy.
One year after her initial symptom of SSc, she had a
scleroderma renal crisis (SRC), with a presenting blood
pressure of 178/76mmHg and creatinine level of 1.77mg/dL.
Microangiopathic hemolytic anemia was not present.
Our patient was hospitalized and her blood pressure
was controlled with an ACE-I. Our patient attended
follow-up visits every other month for the next four
months. Despite well-controlled blood pressure; echo-
cardiogram improvement (normal ejection fraction);
resolution of anemia following treatment for gastric antralvascular ectasia; creatinine stabilization (1.44mg/dL); and
modified Rodnan skin score stabilization (maximum 38),
our patient reported progressive fatigue and weakness. An
electromyogram, nerve conduction studies, and levels of
muscle enzymes were normal, and physical therapy was
prescribed. She reported mild improvement in all symp-
toms at a follow-up visit two months later.
One year after her diagnosis of SSc and two months
after her last clinic appointment, our patient was hos-
pitalized for acute onset left-sided heart failure, with
an ejection fraction of 20% documented by echocardio-
gram. An ECG revealed that her sinus rhythm and car-
diac enzyme levels were normal. A repeat right and left
heart catheterization showed a right atrial pressure of
19mmHg, right ventricular pressure of 64/7mmHg, PA
pressure of 69/27mmHg (mean, 39mmHg), wedge
pressure of 19mmHg, cardiac output of 6.8L/min, car-
diac index of 3.3L/min, and only mild luminal abnor-
malities in her right coronary and left circumflex
arteries. During this hospitalization, our patient stated
that if she were to die, she wished to donate her body
to science to help further physician understanding of
SSc. One day after making this statement, she died of
pulseless electrical activity, despite being followed
closely at a clinic dedicated to SSc care and having no
limitations to access.
An autopsy was immediately performed. She had car-
diac enlargement, right and left ventricular chamber
dilatation, pleural effusions, hepatosplenomegaly, and as-
cites indicative of heart failure. Atherosclerosis of her
right coronary artery with 20% occlusion of the lumen
was identified. Sections of her right and left ventricles,
and septum showed focal interstitial fibrosis (Figure 1).
There was mild perivascular fibrosis in her left ventricle.
Trichrome staining confirmed the presence of collagen;
there were no other microvascular changes. There was
myocyte hypertrophy, but no signs of inflammation. Her
lungs showed moderate interstitial fibrosis, septal thick-
ening, and large arteries with intima fibrosis. Segments
of her esophagus, stomach, small bowel, and large bowel
showed marked collagen deposition in the lamina pro-
pria. There was moderate autolysis without significant
inflammation. Sections of her kidney showed several glo-
bally sclerotic glomeruli, moderate fibrous arterial in-
timal thickening, and interstitial fibrosis. There were no
inflammatory infiltrates, casts, or crystals. There was
glomerular enlargement, nodular increases in mesangial
matrix, and capillary wall thickening consistent with
nodular diabetic glomerulosclerosis. No thrombotic mi-
croangiopathy of the small vessels was noted. Her bone
marrow was hypercellular for age but showed trilineage
hematopoiesis with an approximately normal ratio of
myeloid to erythroid precursors. No other significant ab-
normalities were reported. The pathologist reported her
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Figure 1 (A) Hematoxylin and eosin-stained section shows myocardial tissue with interstitial fibrosis. There is focal myocyte hypertrophy. Inflammation
is not identified. Small artery (arrow) does not show abnormalities. (B) On trichrome stain, the interstitial fibrosis is highlighted in blue and myofibrillar
loss (arrows) is also seen.
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cardial fibrosis and atherosclerosis.
Metabolomics were used to investigate which metabol-
ism and signaling pathways played a key role in her
heart failure. For this investigation, the heart was imme-
diately placed in a −80°C freezer. Subsequent quantita-
tive analysis of a large number of small metabolites
(<1000Da) within a cell or tissue and principle compo-
nent analysis allow maximum variation in the data to be
described, providing a fingerprint of physiological and
pathophysiological status. In our study, the comparative
analyses of metabolomes were performed by a combined
approach of gas chromatography–mass spectrometry
spectroscopic techniques with subsequent computer
analysis of the data generated. Our patient’s tissue was
compared to averages of 79 metabolites in 16 other pa-
tients who suffered cardiac death. In our patient, the es-
sential amino acids (2-aminoadipic acid, lysine, valine,
leucine, alanine, glutamic acid, proline, aspartic acid, as-
paragine, methionine, cysteine, tyrosine, and histidine)
were the most elevated metabolic class. Our patient’s
lipid, peptide, and carbohydrate metabolites were similar
to those in the other 16 patients tested. Of interest, des-
pite her history of SRC, our patient’s creatinine level was
lower than any of the other samples tested.
Discussion
The index case presented here is of a PRESS patient at
high risk for morbidity and mortality, who stated a de-
sire to donate her body to science. As per this patient’s
desire, the PRESS investigators acknowledge that a more
objective and precise system to identify specific cause of
death is needed in rare diseases to better understand
their pathogenesis. This patient was followed closely at a
dedicated SSc clinic, thus her care was guideline based
[2,3]. Nonetheless, the outcome was poor and, despite
appropriate therapeutics, she died suddenly. In SSc
patients, myocardial fibrosis, conduction systemdisease, and autonomic neuropathy are substrates pre-
disposing to supraventricular and ventricular arrhyth-
mias, which in some individuals can cause sudden
death. The use of electroanatomical mapping may
have a role in these patients to reveal possible ar-
rhythmogenic foci [4]. While there are contradictory
reports regarding the prevalence of atherosclerosis in
SSc, it is possible that, in our patient, her longstand-
ing diabetes contributed to her adverse cardiac out-
come [5]. Once cardiac dysfunction becomes apparent
in patients with SSc it can severely increase morbidity
and rapidly lead to death, such as seen in this case.
The etiology of cardiac fibrosis may be repeat ische-
mia and reperfusion injury [6].
The prevalence of primary cardiac involvement in SSc
may be difficult to determine owing to the numerous
possible cardiac manifestations in a phenotypically di-
verse patient population. Histologic studies, which reveal
the presence of myocardial involvement, often disagree
with clinical studies [5]. In our patient, we determined
that metabolomics may provide further information on
her presumed cardiac death. Metabolomics is a powerful
tool to map perturbations in the metabolic system and
enables simultaneous quantification of several metabo-
lites that might provide insights into disease pathogen-
esis [7]. We used metabolomics to provide a systematic
study of the polar metabolites (metabolome) present in
the cardiomyocyte at the time of her death. There are
reported end-point metabolites of biological events after
cardiac arrest and resuscitation [8]. In this pilot study,
the metabolomics approach offered insight into the car-
diac molecule regulation and signaling at the time of our
patient’s presumed cardiac death. The metabolome rep-
resents the complete set of low molecular weight (typic-
ally <1500Da) metabolites produced by an organism,
which are the end products of gene expression, and re-
flects the physiological state of a biological system [9].
Because untargeted metabolomics essentially provides a
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ment, it is useful in biomarker discovery, diagnostics, and
may reveal specific metabolic patterns of disease [9]. In
our patient with diffuse SSc, the primary finding was that
her levels of essential amino acids were elevated. While no
statistical significance could be assigned to these results
because they were from one biological replicate, it is an in-
teresting finding nonetheless. The dibasic amino acids
share plasma membrane transporters with arginine, a rate-
limiting substrate for nitric oxide synthase, which is a crit-
ical mediator of vasodilation [10]. Our patient’s profile was
different from the metabolomic network of seven metabo-
lites reported to be associated with death (gamma-gluta-
mylphenylalanine, gamma-glutamyltyrosine, 1-arachidonoyl
GPC(20:4), taurochenodeoxycholate, 3-(4-hydroxyphenyl)
lactate, sucrose, kynurenine) in patients studied in an
intensive care unit with systemic inflammatory re-
sponse criteria [11].
Historically, autopsy analysis was instrumental for un-
derstanding SSc pathogenesis [12]. Previous autopsy
series of cardiac involvement in SSc describe hyper-
trophy and/or fibrosis primarily of the myocardium;
however, fibrosis of the endocardium, pericardium, and
epicardium has been reported [13,14]. These autopsy
studies suggest that cardiac fibrosis represents a late fea-
ture of disease; however, cardiac remodeling, character-
ized by myocardial fibrosis, particularly within the
interstitium in patients with SSc, can be identified on
endomyocardial biopsy before any signs or symptoms of
heart failure appear [15]. Thus, another important aspect
of this early diffuse SSc case is that left ventricle changes
were comparable to the right ventricle changes at aut-
opsy. This finding highlights that patients with diffuse
SSc may have distinct changes in both the right and left
ventricles, independent of the presence of PAH or heart
failure. In fact, the use of cardiac MRI in SSc, which can
show delayed enhancement consistent with fibrosis,
demonstrates that cardiac involvement is likely more
common than previously recognized on echocardiogram
[16]. The importance of a better understanding of low-
grade endocardial and myocardial inflammation and fi-
brosis in patients with diffuse SSc is paramount for guid-
ing therapy and predicting outcomes [17]. In particular,
the role of ACE-I in diffuse SSc must be clarified be-
cause it may mask SRC [18], yet, as highlighted by this
case, may have a role in cardiac care. Furthermore, this
case highlights a need for renewed attention on the util-
ity of autopsy to enhance our understanding of diffuse
SSc pathogenesis on a molecular level. A delayed-
enhancement cardiac MRI failed to identify myocardial
fibrosis that was present on a histological assessment of
the myocardium following autopsy. Thus, post-mortem
studies may enhance our knowledge of visceral involve-
ment in diffuse SSc.Conclusions
This case highlights the importance of autopsy. Our pa-
tient suffered from the many effects of SSc and re-
quested that her body be donated to science to help
further an understanding of the pathogenesis of SSc. It
is likely that the pace of discovery will dramatically ac-
celerate in SSc research as increasingly comprehensive
screening of the genome, transcriptome, proteome, and
metabolome are applied. To optimize these new tech-
nologies, however, it is critical that autopsy is considered
in patients with SSc to allow tissues for research to be
methodically collected and processed. The PRESS inves-
tigators acknowledge that autopsy holds immense poten-
tial for understanding mechanisms of disease and
facilitating the development of diagnostics, and perhaps
personalized therapeutic strategies, in SSc.
Consent
This patient consented to participate in the PRESS regis-
try and its publications. She was committed to the dis-
covery of pathogenesis in SSc. Written informed consent
was obtained from the patient's next-of-kin for publica-
tion of this case report and any accompanying images. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal.
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